{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:33:53Z","timestamp":1790505233832,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.acvd.2015.06.002","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T08:13:43Z","timestamp":1436861623000},"page":"530-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["How to define valvular atrial fibrillation?"],"prefix":"10.1016","volume":"108","author":[{"given":"Laurent","family":"Fauchier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Philippart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Clementy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Ivanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Babuty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2015.06.002_bib0375","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0380","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2015.06.002_bib0385","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2015.06.002_bib0390","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/eurheartj\/eht039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)","volume":"34","author":"Connolly","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0395","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0400","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0405","doi-asserted-by":"crossref","first-page":"348e1","DOI":"10.1016\/j.ahj.2009.08.026","article-title":"Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment","volume":"159","author":"Eikelboom","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0410","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0415","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0420","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0425","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0430","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-8703(03)00325-9","article-title":"Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)","volume":"146","author":"Halperin","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0435","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u00a0\u2013\u00a0the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0440","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0445","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","article-title":"Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation\u00a0\u2013\u00a0The ARISTOTLE\u00a0\u2013\u00a0J study","volume":"75","author":"Ogawa","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0450","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Executive Steering Committee of the SIIII. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2015.06.002_bib0455","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0460","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0465","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1253\/circj.CJ-11-1140","article-title":"Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation","volume":"76","author":"Yamashita","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0470","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/eurjhf\/hft111","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial","volume":"15","author":"Ferreira","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2015.06.002_bib0475","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0480","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/eurheartj\/eht310.4384","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE study","volume":"310","author":"Avezum","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0485","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2015.06.002_bib0490","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2015.06.002_bib0495","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","volume":"57","author":"Fuster","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0500","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0505","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/0003-4819-52-4-741","article-title":"The course of mitral stenosis without surgery: ten- and twenty-year perspectives","volume":"52","author":"Rowe","year":"1960","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0510","doi-asserted-by":"crossref","first-page":"352S","DOI":"10.1378\/chest.108.4_Supplement.352S","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"108","author":"Laupacis","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2015.06.002_bib0515","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","article-title":"Guidelines on the management of valvular heart disease (version 2012)","volume":"33","author":"Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0520","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/jnnp.37.4.378","article-title":"Cerebral embolism and mitral stenosis: survival with and without anticoagulants","volume":"37","author":"Adams","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.acvd.2015.06.002_bib0525","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1161\/01.STR.0000072274.12041.FF","article-title":"Cerebral ischemic events after diagnosis of mitral valve prolapse: a community-based study of incidence and predictive factors","volume":"34","author":"Avierinos","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2015.06.002_bib0530","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/clc.20433","article-title":"Effect of mitral regurgitation on cerebrovascular accidents in patients with atrial fibrillation and left atrial thrombus","volume":"32","author":"Nair","year":"2009","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0535","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/00005344-200104000-00009","article-title":"Prevention of cerebral thromboembolism by low-dose anticoagulant therapy in atrial fibrillation with mitral regurgitation","volume":"37","author":"Wada","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0540","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0167-5273(99)00208-9","article-title":"Mild mitral regurgitation was associated with increased prevalence of thromboembolic events in patients with nonrheumatic atrial fibrillation","volume":"72","author":"Miyasaka","year":"2000","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0545","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijcard.2009.06.051","article-title":"Relation of the severity of mitral regurgitation to thromboembolic risk in patients with atrial fibrillation","volume":"146","author":"Fukuda","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0550","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0002-8703(98)70231-5","article-title":"Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"136","author":"Nakagami","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0745","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv163","article-title":"Prognostic value of CHA2DS2-VASc score in patients with \u2018non-valvular atrial fibrillation\u2019 and valvular heart disease: the Loire Valley Atrial Fibrillation Project","author":"Philippart","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0560","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1540-8175.2002.00319.x","article-title":"Prevalence and clinical significance of left atrial spontaneous echo contrast detected by transesophageal echocardiography","volume":"19","author":"Vincelj","year":"2002","journal-title":"Echocardiography"},{"key":"10.1016\/j.acvd.2015.06.002_bib0565","first-page":"278","article-title":"Mitral regurgitation reduces systemic coagulation activity in patients with rheumatic heart disease","volume":"18","author":"Cevik","year":"2009","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.acvd.2015.06.002_bib0570","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0002-9149(97)00856-4","article-title":"Effect of mitral regurgitation on coagulation activity in atrial fibrillation","volume":"81","author":"Fukazawa","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0575","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2006.05.021","volume":"48","author":"American College of Cardiology","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199907013410101","article-title":"Prevalence and clinical outcome of mitral-valve prolapse","volume":"341","author":"Freed","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0585","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM199907013410102","article-title":"Lack of evidence of an association between mitral-valve prolapse and stroke in young patients","volume":"341","author":"Gilon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0590","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jacc.2011.09.061","article-title":"Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation","volume":"59","author":"Amat-Santos","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0595","doi-asserted-by":"crossref","first-page":"593S","DOI":"10.1378\/chest.08-0724","article-title":"American College of Chest P.\u00a0Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.)","volume":"133","author":"Salem","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2015.06.002_bib0600","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses","volume":"89","author":"Cannegieter","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2015.06.002_bib0605","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0022-5223(97)70264-2","article-title":"Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves","volume":"113","author":"Meschengieser","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0610","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"Cannegieter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0615","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0002-9149(97)01007-2","article-title":"Long-term follow-up of St-Jude Medical prosthesis in a young rheumatic population using low-level warfarin anticoagulation: an analysis of the temporal distribution of causes of death","volume":"81","author":"Kontozis","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0620","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.06.002_bib0625","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u201cvalvular\u201d atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0630","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/cd.2000.v25.a103682","article-title":"Long-term performance of heart valve prostheses","volume":"25","author":"Grunkemeier","year":"2000","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0635","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0022-5223(19)35640-5","article-title":"Aortic valve replacement with stentless porcine aortic bioprosthesis","volume":"99","author":"David","year":"1990","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0640","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejcts.2008.02.024","article-title":"Guideline on antiplatelet and anticoagulation management in cardiac surgery","volume":"34","author":"Dunning","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0645","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ejcts.2006.12.017","article-title":"Antithrombotic therapy following bioprosthetic aortic valve replacement","volume":"31","author":"Nowell","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0650","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jtcvs.2004.11.028","article-title":"Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?","volume":"129","author":"Sundt","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0655","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0003-4975(10)62897-4","article-title":"Thrombosis and degeneration of Hancock valves: clinical and pathological findings","volume":"26","author":"Hetzer","year":"1978","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0660","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-5223(19)37768-2","article-title":"Pathological substrates of thrombus formation after heart valve replacement with the Hancock bioprosthesis","volume":"80","author":"Thiene","year":"1980","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0665","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/hrt.2007.134726","article-title":"Antithrombotic management in patients with prosthetic valves: a comparison of American and European guidelines","volume":"95","author":"Butchart","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2015.06.002_bib0670","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","article-title":"High risk of thromboemboli early after bioprosthetic cardiac valve replacement","volume":"25","author":"Heras","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0675","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1001\/jama.2012.54506","article-title":"Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding","volume":"308","author":"Merie","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2015.06.002_bib0680","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ejcts.2004.12.064","article-title":"Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial","volume":"27","author":"Aramendi","year":"2005","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0685","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejcts.2007.03.031","article-title":"Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors","volume":"32","author":"Brueck","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0690","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/1089253208328583","article-title":"An argument for routine ultrasound screening of the thoracic aorta in the cardiac surgery population","volume":"12","author":"Whitley","year":"2008","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.acvd.2015.06.002_bib0695","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.05.007","volume":"52","author":"Bonow","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2015.06.002_bib0700","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"American College of Chest P.\u00a0Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2015.06.002_bib0705","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0710","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0022-5223(19)37383-0","article-title":"The risk of thromboembolism and hemorrhage following mitral valve replacement. A comparative analysis between the porcine xenograft valve and Ionescu-Shiley bovine pericardial valve","volume":"87","author":"Gonzalez-Lavin","year":"1984","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0715","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0003-4975(10)61253-2","article-title":"Considerations in selection and management of patients undergoing valve replacement with glutaraldehyde-fixed porcine bioprotheses","volume":"30","author":"Williams","year":"1980","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.acvd.2015.06.002_bib0720","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.2196\/resprot.3014","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: Protocol","volume":"3","author":"Duraes","year":"2014","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.acvd.2015.06.002_bib0725","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0195-668X(03)00201-X","article-title":"A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease","volume":"24","author":"Iung","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0730","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/eurheartj\/ehi426","article-title":"Recommendations for the management of patients after heart valve surgery","volume":"26","author":"Butchart","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.06.002_bib0735","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/europace\/euu178","article-title":"The definition of valvular and non-valvular atrial fibrillation: results of a physicians\u2019 survey","volume":"16","author":"Molteni","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2015.06.002_bib0740","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv193","article-title":"Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term","author":"Breithardt","year":"2015","journal-title":"Eur Heart J"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213615001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213615001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:42:37Z","timestamp":1761745357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213615001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":74,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1875213615001163"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2015.06.002","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to define valvular atrial fibrillation?","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2015.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}